Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹6,880 Cr
verified against source
Revenue YoY
9%
reported change
EBITDA
₹2,181 Cr
latest reported figure
Source
nse xbrl
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Dr. Reddy's delivered a record quarter with INR 6,880 crore revenue (+9% YoY) and INR 2,181 crore EBITDA (+30% YoY), driven by strong US generics (up 9% to $384M) and Europe (up 12% to EUR 59M). EBITDA margin expanded to 31.7% despite SG&A investments. India business grew only 2% YoY due to NLEM price cuts and portfolio pruning, but management expects double-digit growth by year-end, supported by ~10 licensing deals for innovative products. US price erosion remains moderate, and the Mayne portfolio integration is on track. Biosimilar rituximab launch in the US is expected in early FY2025. Key risk: FDA observations at the Bachupally biologics facility (9 observations) could delay biosimilar approvals if not resolved timely.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects India business to exit FY2024 with double-digit growth, driven by licensing deals and focus portfolio expansion.
- Company is on track to launch 25-30 products in the US this fiscal year, with 4 launched in Q2.
- Rituximab biosimilar submitted in April 2023; pre-approval inspection completed. Launch expected in early FY2025 if regulatory issues resolved.
- CFO indicated SG&A as a percentage of sales will be in the 28-29% range for the full year, despite investments in digitalization and brands.
Risks flagged
- US FDA pre-approval inspection resulted in 9 observations. Management believes they are addressable but could delay biosimilar approvals if not resolved timely.
- Despite guidance for double-digit growth by year-end, India business has been range-bound for several quarters. Analyst questioned the timeline for material step-up.
- Price erosion remains a headwind, though moderating. Management noted it fluctuates between high single-digit to low double-digit, impacting revenue growth.
Key quotes
- We are pleased to report a quarter with the highest ever revenue, EBITDA, profit before tax and profit after tax.
- The price erosion always affects certain products that have that went into either a bid or RFP or competitive situation in that particular quarter. It's never broad.
- We are not in a rush to spend this money. It has to be a good deal. It has to be something that will match our strategy.
Research modules